C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement and maintain its listing. The company’s warrants and preferred stock will be adjusted accordingly, and fractional shares will be cashed out. Shareholders do not need to take action, and the stock will trade on a split-adjusted basis starting November 9, 2026.
C3is Inc.'s upcoming reverse stock split is noted here with Pluang's Technology-sector snapshot for context. For readers following Technology stocks, as of Nov 05, 2026 20:52 WIB, out of 150 priced US Technology stocks on Pluang, 46 rose and 101 fell. Notable movers include UMC at USD 14.50 with a 1-day change of -9.71% and Pluang order activity showing 72% Sell / 28% Buy, ASX at USD 34.07 down 9.17% with a typical hold time of 50 Days, and PAYC at USD 245.00 down 8.64% with a typical hold time of 86 Days.
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
